| Literature DB >> 25045522 |
Siew Hui Foo1, Shahada A H Sobah2.
Abstract
UNLABELLED: Hypopituitarism is a rare presentation of Burkitt's lymphoma (BL). The purpose of this report is to present a case of BL presenting with panhypopituitarism and to review other case reports of lymphoma presenting with pituitary dysfunction to highlight the distinguishing features of these cases from other benign aetiologies of pituitary dysfunction such as non-functioning pituitary adenomas. We reviewed a total of 11 cases of lymphoma presenting with pituitary dysfunction published from 1998 to 2013 including the present case. The demographics, clinical presentations, laboratory features, radiological findings, histological diagnosis, treatment administered and outcomes were described. Of the total number of patients, 45.5% of the cases had diffuse large B-cell lymphoma while 27.3% had BL. Anterior pituitary dysfunction was more common than posterior pituitary dysfunction at presentation. The other common associated presenting symptoms were painful ophthalmoplegia, cranial nerve palsies and constitutional symptoms. Hypothalamic-pituitary abnormalities were often demonstrated radiologically to be associated with cavernous sinus and/or stalk involvement. All patients who completed immunochemotherapy responded haematologically. Pituitary dysfunction also improved in most cases although the recovery tended to be partial. In conclusion, a high index of suspicion of underlying malignancy, such as lymphoma, should be present in patients presenting with acute pituitary dysfunction associated with painful ophthalmoplegia, rapidly evolving neurological features, radiological features atypical of a pituitary adenoma and constitutional symptoms. An early diagnosis is essential as prompt initiation of definitive therapy will induce disease remission and recovery of pituitary dysfunction. LEARNING POINTS: Hypopituitarism may be the presenting symptom of lymphoma in the absence of associated overt symptoms or signs of a haematological malignancy resulting in delay in diagnosis and institution of treatment.Pituitary dysfunction due to tumour infiltration has a greater tendency to involve the posterior pituitary and infundibulum resulting in diabetes insipidus and hyperprolactinaemia compared with a non-functioning pituitary adenoma.The common associated symptoms of hypopituitarism due to lymphoma infiltration of the hypothalamic-pituitary system include painful ophthalmoplegia, cranial nerve palsies and constitutional symptoms.Radiological abnormalities of the hypothalamic-pituitary region are usually present and often associated with cavernous sinus or stalk involvement.With early institution of definitive treatment, both haematological response and improvement of pituitary dysfunction are expected although the reversal of hypopituitarism tends to be partial and delayed.A high index of suspicion of underlying malignancy such as lymphoma should be present in patients presenting with acute pituitary dysfunction associated with painful ophthalmoplegia, radiological features atypical of pituitary adenomas and constitutional symptoms to enable early diagnosis and prompt initiation of definitive therapy.Entities:
Year: 2014 PMID: 25045522 PMCID: PMC4100599 DOI: 10.1530/EDM-14-0029
Source DB: PubMed Journal: Endocrinol Diabetes Metab Case Rep ISSN: 2052-0573
Laboratory investigation results upon presentation (July 2013) and with disease progression (August 2013)
|
|
|
|
|
|---|---|---|---|
| Haematology | |||
| Total white (×103/μl) | 7.6 | 7.6 | 4–11 |
| Haemoglobin (g/dl) | 12.4 |
| 11.5–16.5 |
| Platelet (×103/μl) | 157 |
| 150–400 |
| Biochemistry | |||
| Urea (mmol/l) | 3.1 |
| 1.7–8.3 |
| Sodium (mmol/l) |
|
| 135–150 |
| Potassium (mmol/l) |
| 4.0 | 3.5–5.0 |
| Creatinine (μmol/l) |
|
| 44–88 |
| Total protein (g/dl) | 77 | 70 | 66–87 |
| Albumin (g/dl) | 43 | 36 | 35–50 |
| Bilirubin (μmol/l) | 18 | 16 | ≤20 |
| ALP (IU/l) | 101 | 116 | 53–141 |
| ALT (IU/l) |
|
| ≤33 |
| AST (IU/l) |
|
| ≤31 |
| LDH (IU/l) |
|
| 140–271 |
| Creatinine kinase (U/l) |
| 69 | 25–170 |
| Hormonal profiles | |||
| 0800 h cortisol (nmol/l) |
| 119–618 | |
| ACTH (pmol/l) |
| 0–10 | |
| Free thyroxine (pmol/l) |
| 11.8–23.2 | |
| TSH (mU/l) |
| 0.4–5.5 | |
| FSH (IU/l) | 2.0 | 0.8–7.5 (luteal) | |
| LH (IU/l) |
| 0.8–27.1 (luteal) | |
| Oestradiol (pmol/l) |
| 550–845 | |
| Prolactin (mU/l) |
| 59–169 | |
| IGF1 (μg/l) | 25 | 22–197 (age 31–40) |
Bold values are out of the reference range. ALP, alkaline phosphatase; ALT, alanine transferase; AST, aspartate transferase; LDH, lactate dehydrogenase; ACTH, adrenocorticotropic hormone; TSH, thyroid-stimulating hormone; FSH, follicle-stimulating hormone; LH, luteinising hormone; IGF1, insulin-like growth factor 1.

(a) A T1-weighted magnetic resonance imaging (MRI) of the sellar region showing a diffusely enlarged pituitary gland measuring 1.6 (W)×1.1 (H) cm with lateral extensions encasing both cavernous sinuses bilaterally and mild compression of the optic chiasm. (b) A T1-weighted MRI of the sellar region after contrast showing heterogeneous enhancement of the enlarged pituitary gland along with the thickened lateral walls of both cavernous sinuses.

(a) Haematoxylin and eosin stain (20× original magnification). Sheets of monomorphic neoplastic lymphoid cells with pleomorphic nuclei, coarse chromatin and little cytoplasm. (b) Ki-67 stain (4× original magnification). Malignant lymphoid cells stained heavily with a Ki-67 index of 100%.
Demographics, clinical features, treatment and outcomes of 11 patients with lymphoma presenting with pituitary dysfunction
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| PC | 39 | Female | Panhypopituitarism with low cortisol, FSH/LH/oestradiol, FT4/TSH; raised prolactin | Painful ophthalmoplegia, headache, weight loss, anorexia and raised LDH | Pituitary MRI: diffusely enlarged pituitary gland with thickened walls of cavernous sinus | Burkitt's lymphoma (buccal biopsy) | High-dose methotrexate-based chemotherapy, died of neutropenic sepsis 2 months after initial presentation |
|
| 59 | Male | Panhypopituitarism with low cortisol, testosterone, FT4; raised prolactin; DI | Partial left third CN palsy, headache and raised ESR/CRP | Pituitary MRI: diffusely enlarged pituitary gland with cavernous sinus encasement and meningeal enhancement | Diffuse large B-cell lymphoma (adrenal biopsy) | NR |
|
| 67 | Female | Panhypopituitarism | Malaise, weight loss, fever, anaemia, thrombocytopaenia and raised LDH/ESR | Pituitary MRI: partially empty sella | Intravascular large B-cell lymphoma (bone marrow biopsy) | R-CHOP received. haematological remission achieved after 18 months. Complete reversal of hypopituitarism achieved after 2 years |
|
| 70 | Female | Partial hypopituitarism with low FSH/LH, raised prolactin; DI | Right third CN palsy, fatigue and thrombocytopaenia | Pituitary MRI: sellar mass involving the pituitary gland and stalk with extension into right cavernous and sphenoid sinus | High-grade B-cell NHL (pituitary gland histology) | Transsphenoidal pituitary surgery. Died 1 week post-operatively |
|
| 63 | Male | Panhypopituitarism | Left fifth CN palsy, anorexia and night sweats | Pituitary MRI: hypothalamic mass with stalk extension | Diffuse large B-cell lymphoma (liver biopsy) | Remission achieved after several cycles of CNS-targeted chemotherapy. PET–CT negative but hypopituitarism persisted |
|
| 65 | Female | Panhypopituitarism with low ACTH/cortisol, FSH/LH, FT4/TSH and IGF1 | Lethargy, anorexia, pedal oedema and pancytopenia | Pituitary MRI: normal PET: metabolically active areas in the pituitary, neck, axilla and liver CT abdomen: intra-abdominal lymphadenopathy | Diffuse large B-cell lymphoma (liver biopsy) | Haematological remission with reversal of hypopituitarism achieved at 10 months after completion of R-CHOP |
|
| 19 | Female | Panhypopituitarism with low cortisol, FSH/LH and FT4/TSH | Right third CN palsy with proptosis, left breast mass and fatigue | Pituitary MRI: a 2.9×2.5 cm parasellar mass involving the right cavernous sinus with suprasellar extension | Burkitt's lymphoma (breast biopsy) | Intrathecal CODOX-M-IVAC resulted in resolution of pituitary mass with partial reversal of panhypopituitarism |
|
| 26 | Male | DI | Anaemia; raised LDH | Pituitary MRI: small hypophyseal fossa with absence of high signals from posterior pituitary with thickened stalk CT abdomen: bilaterally enlarged kidneys | Burkitt's lymphoma (renal biopsy) | Partial haematological remission achieved after four cycles of EPOCH followed by two cycles of mitoxantrone, cytarabine, dexamethasone and thalidomide |
|
| 63 | Male | Panhypopituitarism with low ACTH/cortisol, FT4/TSH testosterone/DHEA/aldosterone; DI | Left ptosis, miosis, hypohidrosis, anaemia; raised LDH | Pituitary MRI: a 13 mm suprasellar lesion with thickened stalk 18F-FDG PET–CT: high uptake in the pituitary gland, bilateral adrenal glands and apex of the left lung | Diffuse large B-cell lymphoma (pituitary biopsy) | Six cycles of R-CHOP followed by two cycles of high-dose methotrexate-based chemotherapy and autologous haemopoietic stem cell transplant. Complete resolution of all radiological lesions with partial remission of hypopituitarism |
|
| 68 | Male | Panhypopituitarism and DI | Generalised lymphadenopathy | MRI: thickened pituitary stalk | Lymphoma (axillary lymph node biopsy) | Resolution of thickened pituitary stalk but persistence of hypopituitarism after chemotherapy |
|
| 32 | Male | DI | Sixth CN palsy, raised ESR | Gallium-68 scan: uptake in iliac bone and skull with extension into right cavernous sinus | B-cell lymphoma (bone marrow biopsy) | Chemotherapy followed by autologous peripheral stem cell transplant and local radiotherapy. Lymphoma symptoms resolved while DI improved |
PC, present case; FSH, follicle-stimulating hormone; LH, luteinising hormone; FT4, free thyroxine; TSH, thyroid-stimulating hormone; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; DI, diabetes insipidus; CN, cranial nerve; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NR, not reported; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; NHL, non-Hodgkin's lymphoma; PET, positron emission tomography; CT, computed tomography; ACTH, adrenocorticotropic hormone; IGF1, insulin-like growth factor; CODOX-M-IVAC, cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, ifosfamide, etoposide and high-dose cytarabine; EPOCH, cyclophosphamide, epirubicin, vincristine, etoposide and prednisone; 18F-FDG, 18F-fluorodeoxyglucose.